PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 11363343

An interview with David A. Cooper, MD, DSc. Interview by Mark Mascolini.

D A Cooper
View original source ↗Export metadata ↓

Abstract

The source did not provide an abstract. Follow the original record for more information.

Explore related subjects

AcyclovirAustraliaClinical Trials as TopicDeveloping CountriesHIV InfectionsHealth PolicyHumansInterviewNewspaper Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

D A Cooper. 1996. An interview with David A. Cooper, MD, DSc. Interview by Mark Mascolini.. https://pubmed.ncbi.nlm.nih.gov/11363343/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Synthesis, DNA binding and antiviral activity of new uracil, xanthine, and pteridine derivatives.

Some new 6-amino-1,3-dimethyl-5-(substituted methylidene)aminouracils were synthesized. Most of them were cyclized with triethyl orthoformate as a one-carbon source to afford 1,3-dime-thyl-6-substituted pteridine derivatives. Certain uracils gave xanthine instead of the expected pteridine derivatives upon using another one-carbon source such as triethyl orthoacetate or triethyl orthobenzoate. The nucleic acid binding assay revealed that some new compounds showed high affinity, chelation, and fragmentation of nucleic acids whether DNA or RNA contrary to acyclovir that has affinity to DNA only. The antiviral activity of these novel compounds showed that compounds 2e and 2f reduced the cytopathogencity of Peste des petits ruminant virus (PPRV) on Vero cell culture by 60 and 50%, respectively.

Acyclovir↗